Unknown PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT03553238

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma

Sponsor: Nanfang Hospital, Southern Medical University

Conditions Leukemia, Acute Leukemia, Lymphoblastic Leukemia, T Cell

Updated 6 times since 2018 Last updated: Jun 11, 2018 Started: Feb 14, 2016 Primary completion: May 30, 2020 Completion: Aug 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03553238, this PHASE2/PHASE3 trial focuses on Leukemia, Acute and Leukemia, Lymphoblastic and remains ongoing. Sponsored by Nanfang Hospital, Southern Medical University, it has been updated 6 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jul 2023 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2021 — Jul 2023 [monthly]

Unknown Status PHASE2_PHASE3
Sep 2020 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jul 2018 — Sep 2020 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanfang Hospital, Southern Medical University

Data source: Nanfang Hospital, Southern Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China